Medibio (ASX:MEB) has announced that a DSM-V 1 diagnosis will be included as a primary comparator for the purposes of assessing the efficacy of its depression algorithms, MEB-001. …
FDA confirms a diagnostic method for Medibio’s final depression validation trial
May 19, 2022 Australian Biotech
Latest Video
New Stories
-
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Patients welcome the timely PBS listing of rare cancer therapy
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News